Invivyd, Inc. (IVVD): debt financing — Invivyd secures $30M non-dilutive term loan facility with Silicon Valley Bank

Invivyd, Inc.

Up to $30M term loan facility split into three $10M tranches available upon meeting financial covenants and net product revenue milestones.
Interest rate at WSJ prime minus 0.25% (floor 6%, cap 9%), maturity March 1, 2029; prepayment premiums 3%-0% sliding over three years.
Loan secured by substantially all assets excluding IP; financial covenants include minimum net product revenue and minimum cash/EBITDA thresholds.
Proceeds for working capital; company highlights non-dilutive nature and potential FDA alignment on VYD2311 as catalyst.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Invivyd, Inc. incurred term loan of up to $30 million with Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company at the greater of (x) the Wall Street Journal prime rate minus 0.25% (subject to a maturing March 1, 2029.

Instrument: term loan
Principal: up to $30 million
Counterparty: Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company
Rate: the greater of (x) the Wall Street Journal prime rate minus 0.25% (subject to a
Maturity: March 1, 2029
Event: incurrence

Exact text from the filing

On April 18, 2025 (the “Closing Date”), Invivyd, Inc. (the “Company”), entered into a Loan and Security Agreement (the “Loan Agreement”), between the Company, as borrower, and Silicon Valley Bank, a Division of First-Citizens Bank & Trust Company, as lender (the “Lender”). The Loan Agreement provides for a senior secured term loan facility in an aggregate principal amount of up to $30 million

View on SEC.gov

Browse all debt financings →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-056005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.